Hemopexin, Low Endotoxin Level [9013-71-2]

Athens Research

Hemopexin, Low Endotoxin Level [9013-71-2]

9

Cell Based Assays, Animal Studies, In Vitro Diagnostic, Glycosylation, Oxidative Damage, Lung Injury, Infection, Inflammation, Neurogenesis, Kidney Injury, Stroke, bèta-thalassemia, Sickle Cell Anemia, Epilepsy

Research Use Only

≥ 95% by SDS-Page

Hemopexin

Hemopexin is a plasma glycoprotein with the highest known binding affinity for free heme, functioning as a critical scavenger during intravascular hemolysis or cellular injury. Structurally, it comprises two bèta-propeller domains that form a high-affinity heme-binding pocket, enabling it to neutralize heme's oxidative toxicity and facilitate its transport to the liver for iron recycling via CD163 receptors. As an acute-phase reactant, hemopexin synthesis increases during inflammation, though chronic hemolysis often depletes its levels, exacerbating tissue damage. Deficiencies or dysfunction in hemopexin are implicated in hemolytic anemias such as sickle cell disease and bèta-thalassemia, where unbound heme drives endothelial activation, vaso-occlusion, and organ damage. It also correlates with neurologic complications in familial epilepsy due to impaired heme clearance in neural tissues and contributes to sepsis-related mortality by failing to counteract hemoglobin-mediated inflammation. Therapeutically, hemopexin supplementation shows promise in preclinical models, reducing cardiovascular dysfunction in sickle cell mice by 50% and mitigating renal injury in hemolysis. It serves as both a biomarker for hemolytic severity and a potential therapeutic agent to attenuate heme toxicity in transfusion medicine, atherosclerosis, and acute porphyrias.

more then 1 year

Source human plasma non-reactive for HBsAG, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA approved tests.

-20C

41116100